Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Further evidence for action mechanism was provided by assays
2023-09-21
Further evidence for action mechanism was provided by assays using [3H]nisoxetine, a selective NET inhibitor used as standard radioligand for competitive binding experiments. The results showed dose-dependent blocking of [3H]nisoxetine binding by both xylazine and dexmedetomidine. Nisoxetine binds t
-
Laminin 925-933 receptor The subdivision of HT receptors sta
2023-09-21
The subdivision of 5-HT receptors started in the 1950s by Gaddum and colleagues, when they realised that in the guinea pig ileum, the effects of 5-HT could be blocked in part by morphine (M), and in part by dibenzyline (D). Gaddum and Picarelli proposed two receptor classes, 5-HT M and 5-HT D (1957)
-
HT modulates cortical and hippocampal pyramidal cell functio
2023-09-21
5-HT modulates cortical and hippocampal pyramidal cell function in a very complex manner, since most 5-HT receptor subtypes (excitatory as well as inhibitory) are expressed on pyramidal nos inhibitor as well as GABAergic interneurons that exert inhibitory control over pyramidal cells (Leiser et al.,
-
In this study high concentrations mM of thuringiensin were r
2023-09-21
In this study, high concentrations (0.5–4 mM) of thuringiensin were required to stimulate the basal adenylate cyclase activity Fig. 2, Fig. 3, Fig. 4, but low concentrations of thuringiensin (1–100 μM) were sufficient to inhibit the forskolin-stimulated adenylate cyclase activity in rat cerebral cor
-
Extracellular adenosine acts as a local
2023-09-21
Extracellular adenosine acts as a local modulator of cell function via four adenosine receptor subtypes (A1Rs A2AR, A2BR, and A3R) that are involved in numerous physiological and pathophysiological processes [31]. Each is encoded by a separate gene and has different functions, although with some ove
-
Since the introduction of zebrafish into the laboratory many
2023-09-21
Since the introduction of zebrafish into the laboratory, many milestones have been achieved that firmly establish this organism as a prominent genetic model for biology and medicine. Many features make this species an organism of easy maintenance in laboratory which provides advantages to understand
-
During years research efforts at Los Alamos National Laborat
2023-09-21
During 2002–2004years research efforts at Los Alamos National Laboratory (LANL) focused on constructing a quantum computer based on regular arrays build from neutral radical molecules possessing one single unpaired Kif15-IN-1 spin. The idea was built on the ability to manipulate individual electron
-
Although experiments on animals and cells indicate that
2023-09-21
Although experiments on animals and cells indicate that antioxidant and free radical scavenging agents have protective effects against brain damage, the results of preclinical trials are not as encouraging. Edaravone is a type of free radical scavenging drug that was first used as a neuroprotective
-
Because activation of HT A
2023-09-21
Because activation of 5-HT2A receptor is capable of facilitating dopamine cell activity and dopamine release (Bortolozzi et al., 2003), and this action of dopamine is known to mediate rat maternal behavior, especially maternal motivation (Afonso et al., 2007, Febo et al., 2010, Li and Fleming, 2003,
-
An AXL decoy receptor with enhanced GAS
2023-09-21
An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer Nexturastat A australia and a murine breast cancer cell line in grafting a
-
Previous studies have demonstrated that the expression of
2023-09-21
Previous studies have demonstrated that the expression of the Aurora B gene is maximally increased at G2/M phage during mitosis (Honda et al., 2003, Fu et al., 2007, Goldenson and Crispino, 2015), and exhibits an extraordinary upregulation in a number of human cancers (Fu et al., 2007, Kollareddy et
-
After infection with Salmonella those bacteria that are not
2023-09-21
After infection with Salmonella those bacteria that are not targeted by autophagy of the complete Salmonella-containing phagosome (see above) but are living freely in the cytosol can be eliminated by xenophagy, that is direct targeting of the ‘naked’ bacteria to the autophagic pathway. The type III
-
Darifenacin HBr mg There are several AP binding sites in the
2023-09-21
There are several AP-1 Darifenacin HBr mg in the sequence of TIMP-1 promoter [18,19]. EBV could up-regulate TIMP-1 expression by binding to the AP-1 site in the TIMP-1 promoter [18]. IL-32, a newly multi-function cytokine, could activate AP-1, NF-κβ, p38MAPK signal pathways, and induce cytokine exp
-
br Materials and methods br Results and discussion
2023-09-21
Materials and methods Results and discussion Conclusion Introduction Free radicals produced by normal oxidative metabolism in the human body can cause chain oxidation of food, accelerate food deterioration and cause serious problems of food safety (Choe & Min, 2006). Excess free radicals
-
br Conclusion br Competing interests br Funding The
2023-09-21
Conclusion Competing interests Funding The Bolger Prostate Cancer Research Fund (no grant number), the National Institute of General Medical Sciences of the National Institutes of Health (1-R01-GM58553, G. B. Bolger, principal investigator), and the National Cancer Institute of the NIH to t
15854 records 269/1057 page Previous Next First page 上5页 266267268269270 下5页 Last page